ATAdam D Timmis

Adam D Timmis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Adam D Timmis has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • How effective are rapid access chest pain clinics? Prognosis of incident angina and non-cardiac chest pain in 8762 consecutive patients

    by N Sekhri, G S Feder, C Junghans, H Hemingway, A D Timmis

    Objective: To determine whether rapid access chest pain clinics are clinically effective by comparison of coronary event rates in patients diagnosed with angina with rates in patients diagnosed with non-cardiac chest pain and the general population. Design: Multicentre cohort study of consecutive patients with chest pain attending the rapid access chest pain clinics (RACPCs) of six hospitals in England. Participants: 8762 patients diagnosed with either non-cardiac chest pain (n = 6396) or incident angina without prior myocardial infarction (n = 2366) at first cardiological assessment, followed up for a median of 2.57 (interquartile range 1.96–4.15) years. Main outcome measures: Primary end point—death due to coronary heart disease (International Classification of Diseases (ICD)10 I20–I25) or acute coronary syndrome (non-fatal myocardial infarction (ICD10 I21–I23), hospital admission with unstable angina (I24.0, I24.8, I24.9)). Secondary end points—all-cause mortality (ICD I20), cardiovascular death (ICD10 I00–I99), or non-fatal myocardial infarction or non-fatal stroke (I60–I69). Results: The cumulative probability of the primary end point in patients diagnosed with angina was 16.52% (95% confidence interval (CI) 14.88% to 18.32%) after 3 years compared with 2.73% (95% CI 2.29% to 3.25%) in patients with non-cardiac chest pain. Coronary standardised mortality ratios for men and women with angina aged Conclusion: RACPCs are successful in identifying patients with incident angina who are at high coronary risk, but there is a need to reduce misdiagnosis and improve outcomes in patients diagnosed with non-cardiac chest pain who accounted for nearly one third of cardiac events during follow-up.


  • Open Access

    Ivabradine - the first selective sinus node If channel inhibitor in the treatment of stable angina

    by S. Sulfi, A. D. Timmis

    Heart rate, a major determinant of angina in coronary disease, is also an important predictor of cardiovascular mortality. Lowering heart rate is therefore one of the most important therapeutic approaches in the treatment of stable angina pectoris. To date, beta-blockers and some calcium-channel antagonists reduce heart rate, but their use may be limited by adverse reactions or contraindications. Heart rate is determined by spontaneous electrical pacemaker activity in the sinoatrial node controlled by the I(f) current. Ivabradine is the first specific heart rate-lowering agent that has completed clinical development for stable angina pectoris. It is selective for the I(f) current, lowering heart rate at concentrations that do not affect other cardiac ionic currents. Specific heart-rate lowering with ivabradine reduces myocardial oxygen demand, simultaneously improving oxygen supply. Ivabradine has no negative inotropic or lusitropic effects, preserving ventricular contractility, and does not change any major electrophysiological parameters unrelated to heart rate. Randomised clinical studies in patients with stable angina show that ivabradine effectively reduces heart rate, improves exercise capacity and reduces the number of angina attacks. It has superior anti-anginal and anti-ischaemic activity to placebo and is non-inferior to atenolol and amlodipine. Ivabradine therefore offers a valuable approach to lowering heart rate exclusively and provides an attractive alternative to conventional treatment for a wide range of patients with confirmed stable angina.


  • Open Access

    Women in cardiology: a UK perspective

    by A D Timmis, K M English

    Women are particularly under-represented in cardiology in the UK, even though women outnumber men in admissions to medical school. Could this disparity be detrimental to the specialty in this country?


  • Open Access

    Women in UK cardiology: report of a Working Group of the British Cardiac Society

    by A D Timmis, C Baker, S Banerjee, A L Calver, A Dornhorst, K M English, J Flint, M E Speechly-Dick, D Turner

    Although the total number of applications to medical school has not changed substantially in recent years, the proportion of female applicants has increased from 50.5% in 1996 to 58.8% in 2002 (table 1).1 Not only did more women than men apply for medical school in 2002 but proportionately more women were successful (60.4% v 55.3%) and there may now be positive selection bias in favour of women at the point of application. Thus, women applying to UK medical schools in 1996–7 were 1.57 times more likely to be offered a place than similarly qualified men.2


  • The effect of diabetes on heart rate and other determinants of myocardial oxygen demand in acute coronary syndromes

    by K. Foo, N. Sekhri, C. Knight, A. Deaner, J. Cooper, K. Ranjadayalan, A. Suliman, A. D. Timmis


  • Open Access

    Plaque stabilisation in acute coronary syndromes: clinical considerations

    by Adam D Timmis


  • Open Access

    Non-haemorrhagic cardiac tamponade caused by a horse kick

    by C Skene, A D Timmis


  • Open Access

    Effect of diabetes on serum potassium concentrations in acute coronary syndromes

    by K Foo, N Sekhri, A Deaner, C Knight, A Suliman, K Ranjadayalan, A D Timmis

    Objectives: To compare serum potassium concentrations in diabetic and non-diabetic patients in the early phase of acute coronary syndromes. Background: Acute phase hypokalaemia occurs in response to adrenergic activation, which stimulates membrane bound sodium-potassium-ATPase and drives potassium into the cells. It is not known whether the hypokalaemia is attenuated in patients with diabetes because of the high prevalence of sympathetic nerve dysfunction. Methods: Prospective cohort study of 2428 patients presenting with acute coronary syndromes. Patients were stratified by duration of chest pain, diabetic status, and pretreatment with β blockers. Results: The mean (SD) serum potassium concentration was significantly higher in diabetic than in non-diabetic patients (4.3 (0.5) v 4.1 (0.5) mmol/l, p < 0.0001). Multivariate analysis identified diabetes as an independent predictor of a serum potassium concentration in the upper half of the distribution (odds ratio 1.66, 95% confidence interval 1.38 to 2.00). In patients presenting within 6 hours of symptom onset, there was a progressive increase in plasma potassium concentrations from 4.08 (0.46) mmol/l in patients presenting within 2 hours, to 4.20 (0.47) mmol/l in patients presenting between 2–4 hours, to 4.24 (0.52) mmol/l in patients presenting between 4–6 hours (p = 0.0007). This pattern of increasing serum potassium concentration with duration of chest pain was attenuated in patients with diabetes, particularly those with unstable angina. Similar attenuation occurred in patients pretreated with β blockers. Conclusion: In acute coronary syndromes, patients with diabetes have significantly higher serum potassium concentrations and do not exhibit the early dip seen in non-diabetics. This may reflect sympathetic nerve dysfunction that commonly complicates diabetes.


  • Open Access

    Interaction between arrival time and thrombolytic treatment in determining early outcome of acute myocardial infarction

    by J Wilkinson, K Foo, N Sekhri, J Cooper, A Suliman, K Ranjadayalan, A D Timmis

    Background: Shortening prehospital delay has been identified as an important means of improving responses to reperfusion treatment. If this increases the risk profile of the population delivered to hospital, it may paradoxically cause a deterioration in hospital mortality. Objective: To examine the interaction between arrival time (time from onset of chest pain to arrival at hospital) and thrombolytic treatment in determining the early outcome of acute myocardial infarction. Methods: Prospective cohort study of 1723 patients with acute myocardial infarction who were potentially eligible for thrombolytic treatment (ST elevation on ECG; arrival time ≤ 12 hours). Results: All patients were eligible for thrombolysis but only 1098 (80%) received it. Patients who did not receive thrombolytic treatment were older (66 (58–73) v 61 (53–70) years, p < 0.001), more commonly female (32.1% v 24.8%, p < 0.01), and had higher frequencies of previous infarction (28.6% v 15.6%, p < 0.001) and left ventricular failure (37.5% v 26.9%, p < 0.01) than patients who received thrombolytic treatment. For the group as a whole, 30 day mortality was 11.7% and was unaffected by arrival time, but in patients who did not receive thrombolysis an arrival time of ≤ 6 hours was associated with significantly higher 30 day mortality than an arrival time of 6–12 hours (24.3% v 2.6%, p = 0.002). Conversely, in patients who did receive thrombolysis an arrival time of ≤ 6 hours was associated with a lower 30 day mortality than an arrival time of 6–12 hours (8.5% v 14.5%, p < 0.02). Conclusions: Shortening prehospital delay in acute myocardial infarction will tend to increase the risk profile of patients presenting to emergency departments. The data presented here indicate that this may increase hospital mortality if underutilisation of thrombolytic treatment among high risk groups is not diminished.


  • Review: Managing the diabetic patient with angina

    by Kong Foo, Adam D Timmis

    Angina is common in the adult diabetic population. The symptoms of diabetic angina are commonly atypical, and often absent (silent ischaemia). Conventional anti-anginal drugs are effective in diabetic patients, but referral for angiography and consideration of percutaneous or surgical revascularisation is necessary if symptoms persist. Secondary prevention strategies are reviewed within the context of medical and surgical treatment options.